Medicare 2026 Mid-Year Reality Check: The $2,100 Drug Cap, $1.5 Billion in Negotiated Drug Savings, and 2.9 Million Forced Plan Switches Florida Seniors Need to Know About

Data last updated: May 4, 2026 · Florida · 14 min read

Four months into the biggest Medicare overhaul in a generation, my office phone has not stopped ringing. The conversations are not the kind I expected. They are not enthusiastic calls from beneficiaries who finally hit a $2,100 ceiling on their pharmacy costs and felt the relief. They are confused calls from clients who got a letter in November telling them their Medicare Advantage plan was going away, who picked something during the rush of the Annual Enrollment Period in December, and who are now — in April and May — living with a plan that does not include the cardiologist they have seen for eleven years.

I am Vivian Soto, a licensed bilingual independent insurance agent at VS Healthcare Solutions in Orlando. I have spent the last 60 days fielding the predictable post-AEP fallout from one of the most disruptive plan years on record, and I want to walk Florida families through what is actually happening on the ground in 2026 versus what the headline numbers say. Some of these reforms are working better than I expected. One of them — the forced disenrollment crisis — is going to define how I counsel families through the next Annual Enrollment Period this October.

Five 2026 Medicare facts every Florida beneficiary should already know

Most of my clients walked into their AEP appointment last fall with a vague sense that “something was changing with drug coverage.” The actual scope of the 2026 program reset is much larger than that, and the numbers below are now confirmed by CMS and KFF data through the first quarter of the calendar year.

Three of these numbers deserve immediate explanation because they are the ones that changed most from 2025. The Part B standard premium climbed from $185.00 in 2025 to $202.90 in 2026 — a $17.90 monthly increase, or roughly 9.7 percent. That is the largest single-year dollar increase in Part B history. The Part B deductible moved from $257 to $283, an increase of $26. The Part D maximum out-of-pocket exposure rose from the much-publicized $2,000 in 2025 to $2,100 in 2026; CMS adjusted the cap based on the annual percentage increase in average expenditures for covered Part D drugs, as required by the Inflation Reduction Act statute.

The reform that almost no one is talking about is the average standalone Part D plan total premium dropping from $38.31 to $34.50 — a 9.9 percent annual decrease in the year that the program is supposed to be paying for richer drug benefits. That figure comes directly from CMS’s landscape analysis of all 2026 plan filings. Lower premiums plus a hard out-of-pocket ceiling is a structural improvement Medicare beneficiaries have not seen in two decades.

The $2,100 Part D cap: what is actually showing up at the pharmacy counter

The single most important consumer-facing change to Medicare in 2026 is the hard out-of-pocket cap on Part D prescription drug spending. Before the Inflation Reduction Act, beneficiaries on a high-cost specialty regimen could pay $7,000, $10,000, or even more out of pocket in a single calendar year through the donut hole and catastrophic phase. There was no statutory ceiling on patient liability. Starting January 1, 2026 every Medicare beneficiary’s annual out-of-pocket on covered formulary drugs is capped at $2,100, full stop. The cap applies whether you carry a stand-alone Part D plan paired with Original Medicare or a Medicare Advantage Prescription Drug plan.

The mechanism actually works the way the law promised. I have a client in Lake Mary on a brand-name biologic for rheumatoid arthritis whose 2025 calendar-year out-of-pocket was $7,840. In 2026 she hit the $2,100 ceiling on April 9. Every covered formulary refill since then has had a $0 copay at the pharmacy. Compounded over the rest of the year, her household will save roughly $5,500 on a single medication line item. That number is not a marketing projection — it is what came out of her actual Express Scripts statement.

The second piece of the equation is the Medicare Prescription Payment Plan, sometimes called M3P or MPPP. This program lets enrollees spread their annual out-of-pocket up to $2,100 across the calendar year in monthly installments instead of paying the full amount at the pharmacy counter. Sign-up is voluntary and is done through your Part D plan or your Medicare Advantage carrier. CMS finalized automatic renewal for the program starting in 2026, meaning if you signed up in 2025 you continued in 2026 unless you affirmatively opted out. Plans were required to send pre-renewal notices after Open Enrollment and before January 1.

The first ten negotiated drug prices: who saves and how much

January 1, 2026 was the date the federal government finally exercised the price-negotiation authority granted in the 2022 Inflation Reduction Act. Ten high-cost brand-name drugs taken by millions of Medicare beneficiaries had their prices set by Medicare for the first time in program history. CMS calls these the “Maximum Fair Prices.” AARP estimates the negotiated prices will save Part D enrollees a collective $1.5 billion in out-of-pocket expenses in 2026 alone.

The negotiated prices reduce list price by between 38 percent and 79 percent, depending on the drug. They do not automatically translate into a 38-79 percent reduction in what the patient pays at the pharmacy — copays, coinsurance, and the new $2,100 cap interact in ways that vary by plan. But the structural effect is unambiguous. For Florida beneficiaries with diabetes (the state has roughly 1.4 million adults with diagnosed diabetes, many over 65), the four diabetes-related drugs on the negotiation list represent the single biggest 2026 affordability win.

The second negotiation cycle is already underway. CMS announced the next set of 15 additional drugs selected for negotiation in 2025 with prices taking effect in 2027. The future iterations will include more Part B drugs administered in clinics, which is the category most relevant to cancer patients, infusion therapies, and the GLP-1 drugs that were temporarily excluded from the 2026 cycle.

The forced disenrollment crisis: why 2.9 million Advantage members lost their plan this year

This is the story almost no one is telling. While the headlines focus on the drug-cap victory lap, a record number of Medicare Advantage enrollees were forced out of their plans for the 2026 plan year because their carriers exited entire counties or shut down product lines. According to a Johns Hopkins University analysis published in early 2026, the 2026 forced-disenrollment rate hit 10 percent of all Medicare Advantage enrollees — roughly 2.9 million people. Among non-special-needs plans specifically the figure climbed to 12.4 percent. That is a tenfold increase from the 1 percent baseline of just two years earlier.

The reason is structural. Medicare Advantage plans had been growing aggressively for a decade by competing on $0 premiums and richer extras. The economics turned in 2025. CMS finalized risk-adjustment recalibration that effectively reduced per-member payments. Stars-rating bonus calculations got tighter. The 2024 Change Healthcare cyber breach hit MA plan administrative costs. Drug costs in the plan-side benefit kept rising. National carriers responded by trimming the geographies and product designs where they could not earn an acceptable margin. The result: the total number of non-SNP MA-only and MA-Prescription Drug plans nationally declined 10 percent year-over-year, from 3,719 plans in 2025 to 3,373 plans in 2026. Several national carriers including CVS Aetna, Elevance, Humana, and UnitedHealthcare each scaled back plan offerings in at least 100 counties.

The downstream effect in Florida was real but more muted than in the rural Midwest and Mountain West where forced disenrollment crested above 18 percent in some counties. Statewide, Florida still has 611 Medicare Advantage plans available in 2026 with an average monthly premium of about $2.11, and 100 percent of Medicare-eligible Floridians have access to at least one $0-premium MA plan. Inside that statewide average, however, the choice set in individual counties shifted. A few examples from my client conversations this winter:

If you were one of the Florida residents whose Medicare Advantage plan ended December 31, 2025, you got an Annual Notice of Change letter in October announcing the discontinuation. CMS automatically opened a Special Enrollment Period for you and your replacement coverage either kicked in by default (in some cases) or required you to choose a new plan during AEP (October 15-December 7) or the MA Open Enrollment Period (January 1-March 31). If you missed the windows and ended up in a default plan you do not love, your next option is to wait for AEP this October.

Stricter prior authorization rules — the 2026 quality-of-care reform

Buried under the headline reforms, CMS finalized the Contract Year 2026 Final Rule on April 4, 2025 with a series of provisions that materially change how Medicare Advantage plans manage care. The most important is a restriction on plans’ ability to reopen and modify a previously approved inpatient hospital decision. Under the rule, MA plans can only reopen an approved admission for “obvious error or fraud.” Before this rule, plans could retroactively downgrade an approved hospitalization to observation status, leaving beneficiaries with surprise bills and providers with rejected claims.

The 2026 Final Rule also tightened prior-authorization timelines — standard decisions within 7 days, expedited within 72 hours — and required that prior-authorization criteria for inpatient and skilled-nursing decisions match Original Medicare medical-necessity criteria. KFF’s 2025 tracker reported that the average MA enrollee experiences roughly 1.7 prior-authorization requests per year, with 7.4 percent denied at first review — but 81.7 percent of denials are eventually overturned on appeal. The lesson is unchanged: appeal everything.

On April 10, 2026, CMS issued a separate proposed rule on interoperability and electronic prior authorization for drugs billed under Part B. If finalized as written, beginning October 1, 2027, payers would be required to provide a specific reason for every drug prior-authorization denial — not a generic denial code. The proposal is open for public comment through June 15, 2026. This is the first time federal policy has required electronic prior authorization for provider-administered therapies under Medicare Part B, and it is the kind of structural reform that reduces beneficiary frustration over years rather than weeks.

The IRMAA brackets you should know if you sold property, retired, or rolled an IRA

Income-Related Monthly Adjustment Amounts — IRMAA — are surcharges added to your Part B and Part D premiums when your modified adjusted gross income is above a threshold. The 2026 IRMAA calculation uses your 2024 tax return MAGI. Florida retirees who sold a long-held home in 2024, took a large IRA distribution, or executed a Roth conversion may be paying significantly higher Part B and D premiums in 2026 without realizing why.

If you had a one-time income event in 2024 that pushed you across an IRMAA threshold and your income has since dropped — for example you retired, your spouse passed, you got divorced, or you stopped receiving a pension — you can file SSA Form SSA-44 to request a redetermination based on your current income. The Social Security Administration grants the appeal in roughly two-thirds of cases I file. If you need help building the documentation packet, that is a service we provide at no charge to clients.

What the next Medicare Annual Enrollment Period (October 15 – December 7, 2026) is going to look like

This October’s Annual Enrollment Period is going to be the most consequential AEP since 2006. Three forces will shape it:

1. Continued Medicare Advantage market shifts. Carriers that pulled back in 2025-2026 are signaling further re-pricing for 2027. Industry analysts at Oliver Wyman expect another year of plan rationalization. Florida specifically should expect more product simplification — expect fewer total plan options in your county but with cleaner benefit designs.

2. The second wave of negotiated drug prices. The next 15 negotiated drug prices take effect January 1, 2027. CMS announced the selection in early 2025 and the formulas are being finalized this summer. If you take any drug on the second negotiation list, your 2027 plan choice should weigh how each carrier handles the new pricing in their formulary.

3. The new $2,100 Part D OOP cap continues but is indexed. The cap will adjust upward again for 2027. Plan accordingly. Beneficiaries on multiple high-cost specialty drugs benefit most from any plan that aggressively manages formulary positioning of the negotiated drugs.

[5-step Florida action checklist]

1. Pull your January and April 2026 plan EOBs and pharmacy receipts. Add up your year-to-date out-of-pocket against the $2,100 cap. If you are above $1,000 with eight months left, the cap will protect you — but you should also consider enrolling in the Medicare Prescription Payment Plan to smooth your monthly cash flow.
2. Re-verify every doctor and specialist you saw in 2025 is in your 2026 plan’s network. Forced disenrollment changes shifted networks in many Florida counties. Use the carrier’s online provider directory and verify by phone.
3. Check whether any of your 2025 prescriptions are now on the negotiated-price list (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog/Fiasp). If yes, your effective 2026 cost should already be lower — verify your pharmacy is applying the new pricing.
4. If you had a one-time 2024 income event, prepare an SSA-44 packet. Sale of property, retirement, divorce, spouse’s death — any of these qualify. The IRMAA savings on Part B alone average $80-$300 per month for the rest of 2026.
5. Calendar the AEP windows now. AEP for 2027 plans runs October 15 – December 7, 2026. The MA Open Enrollment Period for 2027 runs January 1 – March 31, 2027. Make your plan-selection appointment before October 1.

Frequently asked Medicare 2026 questions

Is the $2,000 Part D out-of-pocket cap actually $2,100 in 2026?

Yes. The Inflation Reduction Act set the cap at $2,000 for 2025. The statute requires CMS to adjust the cap annually based on the percentage increase in average per-capita Part D drug expenditures. CMS adjusted the 2026 cap to $2,100 per the Final CY 2026 Part D Redesign Program Instructions released March 3, 2026. The cap continues to apply universally to every Part D enrollee.

My Medicare Advantage plan ended December 31, 2025. What were my options?

You qualified for a Special Enrollment Period and received a notification letter no later than October 31, 2025. Your default options were: enroll in another Medicare Advantage plan during AEP (Oct 15 – Dec 7), enroll in Original Medicare with a stand-alone Part D plan, or use the MA Open Enrollment Period (Jan 1 – Mar 31, 2026) to change your selection. If you missed all three windows you may still qualify for a SEP if you made a default selection that you now want to change.

Can I switch from Original Medicare to Medicare Advantage right now (May)?

The Medicare Advantage Open Enrollment Period (Jan 1 – Mar 31) closed for the year. You generally cannot switch from Original Medicare to MA right now unless you have a qualifying Special Enrollment Period: you moved out of your plan’s service area, you lost employer coverage, you became eligible for Extra Help / LIS, or your area gained a 5-star plan. Otherwise the next window is October 15-December 7 for January 1, 2027 effective dates.

Are the negotiated drug prices the same at every pharmacy?

The Medicare Maximum Fair Price applies regardless of pharmacy. What can vary is your specific copay or coinsurance, which depends on your plan’s benefit design. CVS, Walgreens, and Florida-region independent pharmacies all follow the negotiated price. Mail order through the plan’s preferred pharmacy may have lower coinsurance.

If I sold my house in 2024 and IRMAA hit me in 2026, can I appeal?

Sale of a personal residence is not by itself one of the eight life-changing events SSA recognizes for an SSA-44 redetermination. However, if your 2024 capital-gains income was elevated by a property sale and your 2025-2026 income has dropped substantially because of retirement, marital change, or loss of pension income, you may still qualify on the underlying retirement or income-loss event. We help Florida clients build the documentation packet.

Will Medicare add GLP-1 drugs (Ozempic, Wegovy) to negotiated prices for weight loss?

The 2026 list does not include GLP-1 drugs prescribed primarily for weight loss. CMS’s authority to negotiate drugs prescribed for weight loss specifically is the subject of ongoing rulemaking. GLP-1 drugs prescribed for diabetes are covered under Medicare Part D today, and Ozempic-equivalent diabetes coverage is unchanged.

How does the $202.90 Part B premium increase compare to past years?

The $17.90 monthly increase from 2025 ($185.00) to 2026 ($202.90) is approximately 9.7 percent. This is one of the largest single-year dollar increases in the program’s history. CMS attributes it primarily to provider-rate inflation and increased projected Part B drug spending. The 2026 Social Security cost-of-living adjustment of approximately 2.5 percent does not fully offset the higher premium for many beneficiaries on average benefits.

Where can I find the official 2026 Medicare & You handbook?

The 2026 edition is published by CMS and is available free at medicare.gov/publications. It is the authoritative source for Original Medicare benefits and 2026 cost-sharing amounts. For Medicare Advantage and Part D plan-specific details, the official Plan Finder at medicare.gov/plan-compare is the place to start.

Why a Florida agent matters in this Medicare year

Independent licensed agents do not charge beneficiaries. Carriers pay agent commissions on enrollments, and Medicare regulates that compensation tightly. When you work with an independent broker like our office, you get access to multiple Medicare Advantage carriers, multiple Medigap carriers, and the full slate of standalone Part D plans — and we are required by CMS to discuss all available options that fit your situation, not just the ones that pay us most.

What I do for Florida clients is essentially three things. First, we run a Plan Finder analysis using your actual prescription list, doctors, and ZIP code. Second, we verify the network on the phone with the carrier — not just on the web directory, because directories are notoriously out of date. Third, we map your annual cost-of-care across plans assuming both your typical year and a worst-case high-claim year. The latter is the analysis most beneficiaries skip and the one that prevents the post-AEP surprise calls I have been fielding all spring.

If you would like to read the longer-form analysis I wrote in April on the choice between Medicare Advantage and Original Medicare plus Medigap in Florida, I covered the four-question decision framework in this post. For households still inside the ACA Marketplace and not yet 65, my 2026 ACA trends post covers the parallel changes coming to the under-65 market. And if you are looking at the broader Florida insurance landscape this year, my analysis of 2026 Florida ACA premium hikes walks through the cost pressures that affect every health-coverage decision in the state.

Sources and data references

1. Centers for Medicare & Medicaid Services. 2026 Medicare Parts A & B Premiums and Deductibles. Fact sheet, November 2025.
2. Centers for Medicare & Medicaid Services. Final CY 2026 Part D Redesign Program Instructions. March 3, 2026.
3. Centers for Medicare & Medicaid Services. Medicare Advantage and Part D Programs Expected to Remain Stable in 2026. October 2025.
4. Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026. Fact sheet, August 2024.
5. Centers for Medicare & Medicaid Services. Contract Year 2026 Final Rule (CMS-4208-F). April 4, 2025.
6. Centers for Medicare & Medicaid Services. 2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule. April 10, 2026.
7. HHS Office of the Assistant Secretary for Planning and Evaluation. Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026. ASPE issue brief, 2024.
8. Kaiser Family Foundation. Analyzing Changes in Medicare Part D Enrollment for 2026. February 2026.
9. Johns Hopkins Bloomberg School of Public Health. 1 in 10 Medicare Advantage Enrollees Face Forced Disenrollment in 2026. 2026.
10. RAND Corporation. Disruptions in Medicare Advantage Coverage in 2026. 2026.
11. AARP. First Medicare-Negotiated Drug Prices Debut in 2026. January 2026.
12. Medicare.gov. Medicare & You 2026. CMS publication 10050. October 2025.

This article is educational and does not constitute individual insurance advice. Premium estimates and IRMAA brackets reflect 2026 published values; check the SSA Initial IRMAA Determination notice you received for your specific calculation. Always verify plan details, networks, and formularies with the carrier before enrolling. VS Healthcare Solutions is a licensed independent insurance agency in the State of Florida.

About the Author

Vivian Soto

Licensed Bilingual Insurance Agent — Orlando, FL

Vivian Soto is a Florida-licensed bilingual (English/Spanish) insurance agent serving families across Orange, Osceola, Seminole, Hillsborough, and Miami-Dade counties. She specializes in the ACA Marketplace, Medicare, life insurance, and supplemental coverage — having filed 500+ ACA applications for Florida families and maintained a 91% renewal retention rate. She works directly with 40+ top carriers including Florida Blue, UnitedHealthcare, Humana, Aetna, and Mutual of Omaha.

500+ ACA Apps Filed 91% Retention Rate Bilingual EN/ES 40+ Carriers

Schedule a Consultation → Email Vivian